14 Dec 2012, BioSpectrum Bureau , BioSpectrum
Singapore: BGI-Shenzhen's wholly owned subsidiary, Beta Acquisition, extended its all cash tender offer to purchase all outstanding shares of common stock of US-based Complete Genomics to 12:00 midnight (New York City time) on Monday, December 31, 2012. The offer was previously scheduled to expire at 12:00 midnight (New York City time) on Friday, December 14, 2012.
Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. The depositary for the offer has indicated that, as of the close of business on December 13, 2012, approximately 14,364,134 shares, or approximately 40 percent, of common stock of complete have been validly tendered in and not withdrawn from the offer, including shares of common stock of complete subject to guaranteed delivery procedures.
BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers. Complete's financial adviser is Jefferies & Company and its legal counsel is Latham & Watkins.